Dual GLP-1/GIP receptor agonists

• US 9,751,926 B2
• Filed: 12/12/2014
• Issued: 09/05/2017
• Est. Priority Date: 12/13/2013
• Status: Expired due to Fees

• Current Assignee: Sanofi
• Original Assignee: Sanofi
• Inventors: Kadereit, Dieter, Lorenz, Katrin, Evers, Andreas, Haack, Torsten, Wagner, Michael, Henkel, Bernd, Lorenz, Martin, Stengelin, Siegfried
• Primary Examiner(s): Ha, Julie
• Assistant Examiner(s): Hellman, Kristina M
• Application Number:
  US14/569,260
• Publication Number:
  US 20150166627A1
• Time in Patent Office: 998 Days
• Field of Search: None
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/57563 Vasoactive intestinal peptide [VIP]; Related peptides
• CPC Class Codes: C07K 14/605 Glucagons

Abstract

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

Claims

1. A peptidic compound of formula (I):

R¹—

Z—

R² 

 

(I),

or a salt or solvate thereof,

wherein Z is a peptide moiety of formula (II);

Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Ile-Gln-X14-Glu-X16-Glu-Ala-Val-X20-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-X40 

 

(II),

wherein;

X14 is an amino acid residue selected from Met, Leu, Nle, Met(O), and Met(O₂),

X16 is an amino acid residue selected from Lys and Glu,

X20 is an amino acid residue selected from Arg, Aib, (S)Me-Lys, (R)Me-Lys, and (S)Me-Orn,

X40 is absent or is Lys,

R¹ is NH₂, and

R² is OH or NH₂.

2. The compound, salt, or solvate of claim 1, which is a glucagon-like peptide (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist.

3. The compound, salt or solvate of claim 1, wherein R² is NH₂.

4. The compound, salt or solvate of claim 1, wherein the peptidic compound has a relative activity of at least 0.04% compared to that of natural GIP at the GIP receptor.

5. The compound, salt or solvate of claim 1, wherein the peptidic compound exhibits a relative activity of at least 0.07% compared to that of GLP-1(7-36) at the GLP-1 receptor.

6. The compound, salt or solvate of claim 1, wherein

X14 is an amino acid residue selected from Met, Leu, Nle, Met(O), and Met(O₂),

X16 is an amino acid residue selected from Lys and Glu,

X20 is an amino acid residue selected from Arg, Aib, (S)Me-Lys, (R)Me-Lys, and (S)Me-Orn, and

X40 is absent.

7. The compound, salt or solvate of claim 1, wherein

X14 is Leu,

X16 is Lys,

X20 is an amino acid residue selected from Aib, (S)Me-Lys, (R)Me-Lys, and (S)Me-Orn, and

X40 is absent.

8. The compound, salt or solvate of claim 1, wherein

X14 is an amino acid residue selected from Met, Leu, Nle, Met(O), and Met(O₂),

X16 is an amino acid residue selected from Lys and Glu,

X20 is Arg, and

X40 is absent or is Lys.

9. The compound, salt or solvate of claim 1, wherein

X14 is an amino acid residue selected from Met, Leu, Nle, Met(O), and Met(O₂),

X16 is Lys,

X20 is Arg, and

X40 is absent or is Lys.

10. The compound, salt or solvate of claim 1, wherein

X14 is an amino acid residue selected from Met and Leu,

X16 is Glu,

X20 is an amino acid residue selected from Arg, Aib, (S)Me-Lys, (R)Me-Lys, and (S)Me-Orn, and

X40 is absent or is Lys.

11. The compound, salt or solvate of claim 1, wherein

X14 is an amino acid residue selected from Leu and Nle,

X16 is an amino acid residue selected from Lys and Glu,

X20 is an amino acid residue selected from Arg, Aib, (S)Me-Lys, (R)Me-Lys, and (S)Me-Orn, and

X40 is absent.

12. The compound, salt or solvate of claim 1, wherein

X14 is an amino acid residue selected from Met, Met(O), and Met(O₂),

X16 is an amino acid residue selected from Lys and Glu,

X20 is Arg, and

X40 is absent.

13. The compound, salt or solvate of claim 1, wherein the compound comprises any one of SEQ ID NOs:

8-20 or a salt or solvate thereof.

14. The compound, salt or solvate of claim 1, wherein the compound is any one of SEQ ID NOs:

10-14 and 16-20 or a salt or solvate thereof.

15. A pharmaceutical composition comprising the compound of claim 1, or a salt or solvate thereof.

16. The pharmaceutical composition of claim 15, together with at least one pharmaceutically acceptable carrier.

17. The pharmaceutical composition of claim 15, further comprising at least one additional therapeutically active agent, wherein the additional therapeutically active agent is selected from the group consisting of:

insulin and insulin derivatives selected from the group consisting of insulin glargine, insulin glusiline, insulin detemir, insulin lispro, insulin degludec, insulin aspart, basal insulin and analogues thereof, pegylated insulin, recombinant human insulin, polysialated insulins, long-acting insulin, NN1045, insulin in combination with pramlintide, PE0139, fast-acting and short-acting insulins, insulin hydrogel, oral insulin, inhalable insulin, transdermal insulin and sublingual insulin, and insulin derivatives which are bonded to albumin or another protein by a bifunctional linker;

GLP-1;

GLP-1 analogues;

GLP-1 receptor agonists selected from the group consisting of lixisenatide, exenatide, ITCA 650, AC-2993, liraglutide, semaglutide, taspoglutide, albiglutide, dulaglutide, rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide, HM-11260C, CM-3, ORMD-0901, NN-9924, NN-9926, NN-9927, CVX-096, ZYOG-1, ZYD-1, GSK-2374697, DA-3091, MAR-701, MAR709, ZP-2929, ZP-3022, TT-401, BHM-034, MOD-6030, CAM-2036, DA-15864, ARI-2651, ARI-2255, xtenylated exenatide, xtenylated glucagon, and polymer bound derivatives thereof;

dual GLP-1/GIP receptor agonists;

dual GLP-1/glucagon receptor agonists;

protein YY_3-36 (PYY3-36);

pancreatic polypeptide;

glucagon receptor agonists;

GIP receptor agonists or antagonists;

ghrelin antagonists or inverse agonists;

xenin;

dipeptidyl peptidase IV (DPP-IV) inhibitors;

sodium glucose cotransporter 2 (SGLT2) inhibitors;

dual SGLT2/SGLT1 inhibitors;

biguanides;

thiazolidinediones;

dual peroxisome proliferator-activated receptor (PPAR) agonists;

sulfonylureas;

meglitinides;

alpha-glucosidase inhibitors;

amylin and pramlintide;

G protein-coupled receptor 119 (GPR119) agonists;

GPR40 agonists;

GPR120 agonists;

GPR142 agonists;

systemic or low-absorbable transmembrane G protein-coupled receptor 5 (TGR5) agonists;

bromocriptine mesylate;

inhibitors of 11-beta-hydroxysteroid dehydrogenase (HSD);

activators of glucokinase;

inhibitors of diacylglycerol acyltransferase (DGAT);

inhibitors of protein tyrosinephosphatase 1;

inhibitors of glucose-6-phosphatase;

inhibitors of fructose-1,6-bisphosphatase;

inhibitors of glycogen phosphorylase;

inhibitors of phosphoenol pyruvate carboxykinase;

inhibitors of glycogen synthase kinase;

inhibitors of pyruvate dehydrogenase kinase;

alpha2-antagonists;

C—

C motif receptor (CCR-2) antagonists;

modulators of glucose transporter-4;

somatostatin receptor 3 agonists;

3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA)-reductase inhibitors;

fibrates;

nicotinic acid and derivatives thereof;

nicotinic acid receptor 1 agonists;

PPAR-alpha, gamma, or alpha/gamma agonists or modulators;

PPAR-delta agonists;

acyl-CoA cholesterol acyltransferase (ACAT) inhibitors;

cholesterol absorption inhibitors;

bile acid-binding substances;

ileal bile acid transporter (IBAT) inhibitors;

microsomal triglyceride transfer protein (MTP) inhibitors;

modulators of proprotein convertase subtilisin/kinexin type 9 (PCSK9);

low-density lipoprotein (LDL) receptor up-regulators by liver selective thyroid hormone receptor β

agonists;

high-density lipoprotein (HDL)-raising compounds;

lipid metabolism modulators;

phospholipase A2 (PLA2) inhibitors;

apolipoprotein A1 (ApoA-1) enhancers;

thyroid hormone receptor agonists;

cholesterol synthesis inhibitors;

omega-3 fatty acids and derivatives thereof;

substances for the treatment of obesity selected from the group consisting of sibutramine, tesofensine, tetrahydrolipstatin, cannabinoid-1 (CB-1) receptor antagonists, melanin-concentrating hormone-1 (MCH-1) antagonists, melanocortin 4 (MC4) receptor agonists and partial agonists, neuropeptide Y5 (NPY5) or NPY2 antagonists, NPY4 agonists, beta-3-agonists, leptin or leptin mimetics, agonists of the 5-hydroxy tryptophan 2c (5HT2c) receptor, combinations of bupropione/naltrexone, combinations of bupropione/zonisamide, combinations of bupropione/phentermine, combinations of pramlintide/metreleptin, and combinations of phentermine/topiramate; and

lipase inhibitors;

angiogenesis inhibitors;

H3 antagonists;

Agouti-related protein (AgRP) inhibitors;

triple monoamine uptake inhibitors;

methionine aminopeptidase type 2 (MetAP2) inhibitors;

nasal formulation of the calcium channel blocker diltiazem;

antisense molecules against production of fibroblast growth factor receptor 4;

prohibitin targeting peptide-1; and

drugs for influencing high blood pressure, chronic heart failure, or atherosclerosis selected from the group consisting of angiotensin II receptor antagonists, angiotensin-converting-enzyme (ACE) inhibitors, endothelin-converting-enzyme (ECE) inhibitors, diuretics, beta-blockers, calcium antagonists, centrally acting hypertensives, antagonists of the alpha-2-adrenergic receptor, inhibitors of neutral endopeptidase, and thrombocyte aggregation inhibitors.

18. The pharmaceutical composition of claim 15, together with at least one additional therapeutically active agent, wherein the at least one additional therapeutically active agent is selected from the group consisting of a GLP-1 agonist, an insulin, an insulin analogue, and a gastrointestinal peptide.

19. A solvate of a compound of claim 1.

20. A hydrate of a compound of claim 1.

21. A method of treating a disease or disorder comprising administering to a patient in need thereof the pharmaceutical composition of claim 15, wherein the disease or disorder is selected from the group consisting of hyperglycemia, type 2 diabetes, type 1 diabetes, and obesity.

22. The method of claim 21, wherein the disease or disorder is selected from the group consisting of hyperglycemia, type 2 diabetes, and obesity.

23. The method of claim 21, wherein the method delays the progression of impaired glucose tolerance (IGT) to type 2 diabetes or the progression of type 2 diabetes to insulin-requiring diabetes.

24. The method of claim 21, wherein the method regulates appetite or induces satiety.

25. A method of treating hyperglycemia, type 2 diabetes, or obesity in a patient, the method comprising administering to the patient an effective amount of at least one compound of formula I, or a salt or solvate thereof, according to claim 1 and an effective amount of at least one additional compound for treating hyperglycemia, type 2 diabetes, or obesity.

26. The method of claim 25, wherein the effective amounts of the at least one compound of formula I, or a salt or solvate thereof, and of the at least one additional compound are administered to the patient simultaneously.

27. The method of claim 25, wherein the effective amounts of the at least one compound of formula I, or a salt or solvate thereof, and of the at least one additional compound are administered to the patient sequentially.